Intracellular Antimicrobial Activity in the Absence of Interferon-γ: Effect of Interleukin-12 in Experimental Visceral Leishmaniasis in Interferon-γ Gene-disrupted Mice

By Alice P. Taylor and Henry W. Murray

Summary

Despite permitting uncontrolled intracellular visceral infection for 8 wk, interferon-γ (IFN-γ) gene knockout (GKO) mice infected with Leishmania donovani proceeded to reduce liver parasite burdens by 50% by week 12. This late-developing IFN-γ-independent antileishmanial mechanism appeared to be dependent largely on endogenous tumor necrosis factor-α (TNF-α); L. donovani infection induced TNF-α mRNA expression in parasitized GKO livers and neutralization of TNF-α reversed control at week 12. 7 d of treatment of infected GKO mice with interleukin-12 (IL-12) readily induced leishmanicidal activity and also partially restored the near-absent tissue granulomatous response; observations that for the first time expand the antimicrobial repertoire of IL-12 to include IFN-γ-independent effects. The action of IL-12 against L. donovani was TNF-α dependent and required the activity of inducible nitric oxide synthase. These results point to the presence of an IFN-γ-independent antimicrobial mechanism, mediated by TNF-α, which remains quiescent until activated late in the course of experimental visceral leishmaniasis. However, as judged by the effect of exogenous IL-12, this quiescent mechanism can readily be induced to rapidly yield enhanced intracellular antimicrobial activity.

Materials and Methods

In endogenous and exogenous form, IFN-γ plays a critical role in the control of experimental visceral leishmaniasis, an intracellular infection caused by the protozoan, Leishmania donovani (1, 2). A role for IFN-γ-independent antileishmanial mechanisms in the control or resolution of visceral leishmaniasis has been suggested (1) but not yet systematically analyzed in an in vivo environment guaranteed to be IFN-γ free. IFN-γ gene knockout (GKO) mice (3) provide such an IFN-γ-free system and have been used in a variety of experimental models (3-8). The results reported here in L. donovani-infected GKO mice point clearly to the presence of a novel IFN-γ-independent antileishmanial mechanism. This mechanism is mediated by endogenous TNF-α and can be induced by exogenous IL-12.
lular infiltrate, (c) a developing granuloma with Kupffer cell fusion and some cellular infiltrate, or (d) as a mature granuloma with the fused core surrounded by a well-developed mononuclear cell mantle (11).

**RNA Extraction and Qualitative Reverse Transcriptase-PCR.** Approximately 50-mg pieces of liver were homogenized in guanidine isothiocyanate-phenol solution (R N A zol B; Tel-Test, Inc., Friendswood, TX) according to manufacturer's instructions. cDNA was synthesized from ∼2 μg of total RNA by standard methods using oligo(dT)18 and MuMLV reverse transcriptase (R T) (9). cDNA was amplified in a 50-μl reaction volume containing the following: each primer at 2 μM, 200 μM dNTP, 5 μl 10× buffer with magnesium supplied by the enzyme manufacturer (Boehringer Mannheim, Indianapolis, IN), and 1 μl of Taq polymerase. For qualitative PCR, the number of cycles (e.g., 34–40) was varied to optimize yield of product. As a control for equal input cDNA, each sample was amplified for GADPH (12).

Primer. IFN-γ: sense, GAG GAA TTC CTA GCT CTG AGA CAA TGA AAG GTG GT; antisense, TCA AGG ATC CGA ATC AGC AGC GAC TCC T (13). GADPH: sense, GAT AGA CAA TGA ACG CTA; antisense, TCA TGC TCA GTG TCC TTG CTG (13). TNF-α: commercially available primers from Stratagene (La Jolla, CA). iNOS: sense, TCA CGC TG TGG CT TGT GAC TAC; antisense, TTG TCT CGT GGT CCT CTG GTC A (14).

**Treatment with IL-12.** Groups of 3–6 mice were continuously treated for 1 wk with 1 μg/day of murine rIL-12 (7.8 x 10^6 U/mg; Genetics Institute, Cambridge, MA) suspended in saline containing 1 mg/ml of BSA (10). Subcutaneous osmotic pumps provided 7 d of continuous treatment with IL-12 or saline/BSA (Alzet model 2001; Alza Corp., Palo Alto, CA). Pumps were implanted 14 d after infection.

**Treatment of Mice with anti-TNF-α Antiserum.** 0.2 ml of rabbit anti-murine TNF-α antiserum or normal rabbit serum was injected intraperitoneally starting on the indicated day after infection and twice-weekly thereafter (15). The anti-TNF-α antiserum contained 3 mg/ml IgG with neutralizing activity of 5 x 10^4 U/mg of protein (15).

**Inhibition of Inducible Nitric Oxide Synthase.** Aminoguanidine (AG) (Sigma), used as an inducible nitric oxide synthase (iNOS) inhibitor (16), was given to mice as a 1% solution in drinking water (wt/vol) starting 12 h after infection and continued for 4 wk. Water was replaced weekly. At 2 and 4 wk, liver parasite burdens were determined in AG-treated and untreated controls.

**Analysis of Data.** Data were subjected to a two-tailed Student's t test. P values of <0.05 were considered significant.

**Results**

**Course of L. donovani Infection in GKO Mice.** Whereas visceral infection was controlled by week 4 in IFN-γ gene-intact littermates (GKO+/+ or GKO+/−) and in normal BALB/c mice, liver parasite burdens increased dramatically in GKO mice during the first 8 wk (Fig. 1). These results confirmed the critical role of endogenous IFN-γ in initial control of L. donovani (1). However, after week 8, parasite burdens in GKO mice decreased significantly, falling to 50% of peak levels by week 12 (P <0.05). The results at week 12 indicated that resolution of visceral leishmaniasis is initiated by a late-acting IFN-γ independent mechanism. In one experiment, there were sufficient GKO mice to extend limited observations to week 16. In this experiment, mean (± SEM) liver parasite burdens peaked at week 8 (8932 ± 557, n = 3) and declined to 5198 ± 1457 (n = 3) and 4582 ± 60 (mean ± range, n = 2) at weeks 12 and 16, respectively. Granulomatous Tissue Response. Effective control over visceral replication and eventual resistance to L. donovani is expressed in the tissues by the assembly of influting T cells and monocytes into granulomas at the sites of infection (11). In this model, hepatic granulomas consist of a core of fused parasitized Kupffer cells surrounded by a mononuclear cell mantle comprised of influting CD4+ and CD8+ cells and monocytes (11, 17). As shown in Table 1, control BALB/c mice displayed the kinetics of granuloma formation already reported in previous studies (11, 17, 18); however, the GKO tissue response in the liver differed considerably.

2 wk after infection, 70% of all infected foci in BALB/c controls had provoked some tissue response, including mature granuloma formation (Table 1). GKO mice, on the other hand, showed a scant response to L. donovani at week 2 with 80% of parasitized foci consisted of unfused infected Kupffer cells with no surrounding mononuclear cells. By week 4, 56% of BALB/c foci were scored as mature granulomas, structures rarely seen (6%) at this timepoint in GKO mice (Fig. 2). However, by week 8, there was evidence of some response at GKO foci, and by week 12, about one in five GKO foci consisted of fully developed granulomas. Overall, these results clearly indicate that endogenous IFN-γ regulates optimal recruitment of influting T cells and monocytes and therefore is required for the initiation of the granulomatous response early in infection. Nevertheless, there...
is also some mature granuloma formation in the absence of IFN-\(\gamma\), reflecting the effect of a late-acting IFN-\(\gamma\)-independent response.

**Role of Endogenous TNF-\(\alpha\) in GKO Mice.** Because TNF-\(\alpha\) is essential to the resolution of *L. donovani* infection in normal BALB/c mice (15), we next focused on TNF-\(\alpha\) as a mechanism that might permit GKO mice to reduce liver parasite burdens after week 8.

TNF-\(\alpha\) mRNA expression in liver was examined using a qualitative RT-PCR assay in which results can be read only as positive (visualized on agarose gel) or negative (not visualized). Although a negative result in this assay does not imply the absence of cytokine mRNA, conversion within groups of mice from negative to largely positive qualitative results, either as infection progressed or after treatment was given, suggests enhanced mRNA expression. As shown in Table 2 and Fig. 3, TNF-\(\alpha\) mRNA was not detected in GKO livers using this assay at week 2 but was detected in an increasingly greater proportion of mice as visceral infection peaked (week 8) and began to resolve (week 12). In livers of infected normal BALB/c mice (Table 2), this assay yielded qualitative results that suggested differences in the kinetics of TNF-\(\alpha\) mRNA expression in that expression was detected earlier and waned by weeks 8–12. These latter

**Figure 2.** Liver histologic reaction in *L. donovani*-infected GKO mice and response to IL-12 treatment. (A) Normal BALB/c mouse shows mature granuloma formation surrounding fused parasitized Kupffer cell core 4 wk after infection. (B) 4-wk-infected GKO liver showing three large heavily parasitized foci (arrows) with minimal mononuclear cell infiltrate. (C) 3-wk-infected untreated GKO mouse showing heavily infected Kupffer cell focus with no cellular infiltrate. (D) 3-wk-infected GKO mouse treated with IL-12 during the preceding 7 d shows few parasites (arrow) and clearly enhanced cell influx. Original magnification, \(\times\)630.
IL-12 Enhances IFN-γ-independent Antileishmanial Activity

Results appeared to mirror the more rapid onset of acquired resistance and control over infection in normal, IFN-γ-intact mice (see Fig. 1). To analyze the role of TNF-α in the IFN-γ-independent antileishmanial mechanism, infected GKO animals were treated with anti-TNF-α antiserum starting at week 8. In untreated GKO controls, parasite burdens peaked at week 8 and then declined (Table 3). Injections of anti-TNF-α reversed this control, whereas injections of normal rabbit serum had no effect. These results indicated that endogenous TNF-α is required for the control of infection after week 8 in GKO mice, suggesting that TNF-α secretion likely represented a key IFN-γ-independent antileishmanial mechanism.

Response of GKO Mice to Exogenous IL-12. To determine whether we could activate this initially quiescent IFN-γ-independent mechanism in infected mice, we examined the effect of exogenous IL-12. Whereas IL-12 is a potent inducer of IFN-γ expression (Table 4) (19–23) and stimulates IFN-γ-dependent antileishmanial activity in normal BALB/c mice (10), some reports indicate possible IFN-γ-independent actions of IL-12 as well (6, 22, 23). GKO mice were continuously treated with IL-12 starting 2 wk after infection, and liver burdens were measured 7 d later. During this period, the parasite burden doubled in untreated mice (Table 5). In contrast, liver burdens were reduced in IL-12-treated animals by 34% (week 3 LDU (1687 ± 300) versus week 2 LDU in controls (2556 ± 468)) indicating induction of L. donovani killing. Thus, the IFN-γ-independent mechanism identified here was indeed sensitive to cytokine upregulation, and despite the absence of IFN-γ, IL-12 was nevertheless quite capable of stimulating an antileishmanial response.

The IFN-γ-independent action of IL-12 was also evident in the tissue histologic response in GKO mice. In untreated 3-wk infected GKO mice, 2% of infected foci were scored as mature granulomas (two experiments; n = 4 mice; see Fig. 2). In contrast, in the same GKO mice treated with IL-12 for 7 d, 31% of infected foci were scored as mature granulomas (n = 4 mice; see Fig. 2). This 15-fold increase in mature granuloma formation thus correlated with IL-12-induced IFN-γ-independent reduction in liver parasite burdens.

Table 2. Expression of TNF-α mRNA in L. donovani-infected Liver

| Weeks after infection | Strain  | TNF present no. samples/total (%) |
|----------------------|---------|----------------------------------|
| Uninfected           | GKO     | 0/4 (0)                          |
|                      | BALB/c  | 0/5 (0)                          |
| 2                    | GKO     | 0/6 (0)                          |
|                      | BALB/c  | 3/6 (50)                         |
| 4                    | GKO     | 3/6 (50)                         |
|                      | BALB/c  | 5/6 (83)                         |
| 8                    | GKO     | 5/6 (83)                         |
|                      | BALB/c  | 3/6 (50)                         |
| 12                   | GKO     | 6/6 (100)                        |
|                      | BALB/c  | 1/6 (17)                         |

Qualitative RT-PCR was performed using cDNA liver samples isolated at the designated timepoints. Results are from 2–3 experiments at each timepoint.

Figure 3. Kinetics of TNF-α mRNA expression in BALB/c mice (A) and GKO mice (B). Qualitative RT-PCR was performed using cDNA from liver RNA extracted at each timepoint. Each lane represents one mouse. Lane 1, size markers; lane 2, PCR control; lanes 3 and 4, 2 wk after infection; lanes 5 and 6, 4 wk after infection; lanes 7 and 8, 8 wk after infection; lanes 9 and 10, 12 wk after infection. Similar results were obtained from six mice for each timepoint.
Table 3. Effect of Anti–TNF-α on Visceral Infection in GKO Mice

| Treatment during weeks 8-12 | Liver Parasite Burden (LDU) |
|-----------------------------|----------------------------|
|                             | Week 8  | Week 12  |
| None (control)              | 9,788 ± 579 | 4,187 ± 636 |
| Normal serum                | 3,943 ± 469 |          |
| Anti–TNF-α                  | 10,202 ± 1,361 |          |

Starting 8 wk after infection, GKO mice were injected twice-weekly with either normal rabbit serum or anti–TNF-α antiserum. Results are mean LDU ± SEM from two experiments with 5–6 mice per group. P < 0.002 for anti–TNF-α-treated group versus untreated and normal saline-treated mice.

Role of TNF-α in IL-12 Action in GKO Mice. Effects of IL-12 unrelated to IFN-γ include upregulation of other cytokines including TNF-α and GM-CSF (23–25), both of which induce antileishmanial activity (10, 12). To investigate whether the IFN-γ-independent, IL-12-induced antileishmanial response involved TNF-α, 2-wk infected GKO mice were injected twice-weekly with anti–TNF-α antiserum or normal serum during 7 d of IL-12 administration. As shown in Table 5, there was some nonspecific inhibition of the effect of IL-12 by simultaneous administration of control serum; however, injections of anti–TNF-α totally abolished the antileishmanial activity induced by IL-12.

Interaction of IL-12, TNF-α, and iNOS in GKO Mice. Activated macrophages use at least two mechanisms for killing intracellular pathogens: the generation of reactive oxygen intermediates and the induction of l-arginine-dependent toxic reactive nitrogen intermediates (26–34). The latter includes nitric oxide (NO), the toxic product of iNOS (30, 35, 36), the induction of which is controlled by cytokines, e.g., TNF-α in combination with IFN-γ (28), and other stimuli including intracellular pathogens as well (27). Therefore, we completed this analysis by investigating the mobilization of iNOS as an antileishmanial effector mechanism in IL-12-treated GKO mice.

Table 4. IL-12-induced Upregulation of IFN-γ in Normal BALB/c Mice

| Treatment of mice | IFN-γ (pg/ml) |
|-------------------|---------------|
|                   | Supernatant   | Serum       |
| Saline/ BSA       | 12 ± 9        | 304 ± 271   |
| IL-12             | >3,000        | >3,000      |

Table 5. Effect of IL-12 on Visceral Infection in GKO Mice

| Treatment | Liver parasite burdens (LDU) |
|-----------|------------------------------|
|           | Week 2 | Week 3 |
| None (control) | 2,556 ± 468 (9) | 5,343 ± 777 (8) |
| IL-12     | 1,687 ± 300 (8)* |          |
| IL-12 plus anti–TNF-α | 8,514 ± 782 (8)† |          |
| IL-12 plus control antiserum | 2,725 ± 288 (9)‡ |          |
| Saline plus control antiserum | 6,428 ± 826 (5) |          |

*Significantly different (P < 0.05) from control mice at week 2 and 3.
†Significantly different (P < 0.05) from control mice at week 3.
‡Significantly different (P < 0.05) from control mice at week 3.

iNOS mRNA was not detected in livers of normal uninfected BALB/c mice by qualitative RT-PCR, but was detected in these animals at week 3 (3 of 6 mice), and week 4 (5 of 5 mice) after infection (Fig. 4). Although not detected

Figure 4. Expression of iNOS mRNA in livers of L. donovani-infected BALB/c mice. Total liver RNA was isolated at 2, 3, and 4 wk after infection and assayed for the presence of iNOS message by qualitative RT-PCR. Each lane represents one mouse. GADPH is a control for the amount of cDNA in each sample. (A) iNOS RT-PCR: lane 1, size markers; lane 2, PCR control; lanes 3, 4, and 5, 2-wk samples. GADPH RT-PCR: lane 1, size markers; lane 2, PCR control; lane 3, blank; lanes 4, 5, and 6, 2-wk samples. (B) iNOS RT-PCR: lanes 1, 2, and 3: 3-wk samples; lanes 4, 5, 6, and 7, 4-wk samples from a different gel and PCR reaction. GADPH RT-PCR, same as iNOS.
Table 6. iNOS mRNA Expression in Livers of GKO Mice

| Time after infection and treatment | iNOS Detected | N o. samples (%) |
|-----------------------------------|---------------|-----------------|
| U ninfected                       | 0/3 (0)       |                 |
| 2 Weeks                           | 1/6 (17)      |                 |
| 3 Weeks                           | 0/6 (0)       |                 |
| 3 Weeks plus IL-12                | 4/6 (67)      |                 |
| 3 Weeks plus IL-12 plus anti-TNF  | 0/6 (0)       |                 |
| 3 Weeks plus IL-12 plus control serum | 4/5 (80)  |                 |
| 4 Weeks                           | 4/8 (50)      |                 |

Liver RNA was assayed for the expression of iNOS message by qualitative RT-PCR. Where indicated, IL-12 treatment (1 μg/d for 7 d) was begun at the end of week 2 with or without simultaneous twice-weekly injections of anti-TNF-α or normal rabbit serum. Results are from 2-3 experiments at each timepoint.

in GKO mice at week 3 (0 of 6 mice), iNOS mRNA was detected at week 4 (4 of 8 mice) (Table 6).

To assess the activity of NO in control of visceral infection in this model, iNOS was inhibited by oral treatment with AG (16). In initial experiments, normal BALB/c mice and wild-type GKO littermates (GKO +/+ ) were treated continuously for 4 wk starting 1 d after infection. As shown in Table 7, AG treatment inhibited control of visceral infection and allowed a three- to four-fold increase in liver parasite burdens, indicating an antileishmanial role for iNOS in normal animals.

Whereas untreated GKO mice did not express detectable iNOS mRNA 3 wk after infection (0 of 6 mice), iNOS mRNA was detected in the same mice treated for the previous 7 d with IL-12 (4 of 6 mice; Table 6). This in vivo relevance of this effect of IL-12 was tested by simultaneously treating GKO mice with IL-12 and AG. As shown in Table 8, in the presence of AG, the capacity of IL-12 to induce antileishmanial activity was abrogated. Finally, to determine whether IL-12-stimulated upregulation of iNOS involved TNF-α, a known participant in iNOS induction (37), we analyzed liver RNA from GKO mice treated with both IL-12 and anti-TNF-α. Anti-TNF-α injections abolished qualitative detection of iNOS mRNA in IL-12-treated animals (see Table 6).

Discussion

We used GKO mice and a well-established model of experimental visceral leishmaniasis to characterize host defense responses to intracellular infection in the absence of IFN-γ. Not surprisingly (1), without endogenous IFN-γ, high parasite burdens developed and persisted weeks beyond the time infection was controlled in IFN-γ-intact animals. However, despite the key role of macrophage-activating endogenous IFN-γ in the early phases of this infection (1, 2), untreated GKO mice nonetheless prevented unrestrained infection and reduced liver parasite burdens after week 8. Thus, because GKO mice produce no IFN-γ, the presence of a late onset IFN-γ-independent antileishmanial mechanism appears unequivocal. GKO mice have also been used in other experimental models to demonstrate IFN-γ-independent control over infection (4, 8, 45).

While the nature of the antileishmanial mechanism uncovered here may be multifactorial, our results point to endogenous TNF-α as a primary effector component. In addition, although persistently quiescent (for unclear reasons) in the initial stages of visceral infection, this mechanism can be readily activated early on, as judged by the effects of treatment with exogenous IL-12. This latter result also clearly expands the host defense repertoire of IL-12 beyond the induction of IFN-γ (10, 22, 24), the most widely studied antimicrobial action of IL-12. Although our data character-

Table 7. Effect of Aminoguanidine on L. donovani-infected Normal Mice

| Strain AG Treatment | Liver parasite burden (LDU) |
|---------------------|-----------------------------|
|                     | Week after infection        |
| BALB/c              |                             |
| 2                   | 1,748 ± 125 (6)             |
|                     | 569 ± 127 (9)               |
| +                   | 1,746 ± 74 (6)              |
|                     | 2,450 ± 255 (9)*            |
| GKO +/+             |                             |
| 2                   | 2,854 ± 214 (3)             |
|                     | 978 ± 213 (6)               |
| +                   | 2,166 ± 81 (3)              |
|                     | 2,919 ± 194 (6)*            |

12 h after L. donovani challenge, treatment with 1% AG was begun and given continuously for 4 wk. Results are mean ± SEM values for (n) mice from two experiments in BALB/c mice and one experiment in GKO +/+ mice.

*Significantly different from 4-wk untreated control value (P <0.05)

Table 8. Effect of iNOS Inhibitor in IL-12-treated GKO Mice

| Treatment started after week 2 | Liver parasite burden (LDU) |
|--------------------------------|-----------------------------|
|                                | W weeks after infection      |
|                                | 2                           |
|                                | 3                           |
| N one (control)                | 2,251 ± 578                 |
|                                | 4,665 ± 611                 |
| IL-12                          | −                           |
|                                | 1,539 ± 338*                |
| IL-12 plus AG                  | −                           |
|                                | 4,545 ± 717                 |

Starting 2 wk after infection, GKO mice were treated with IL-12 (1 μg/day) for 7 d with or without the addition of 1% AG to the drinking water. Results are mean LDU ± SEM values from two experiments with 6-10 mice per timepoint.

*Significantly different (P <0.05) from control mice at week 3.
ize the IFN-γ-independent effect of exogenous IL-12, we have not yet determined the possible role of endogenous IL-12 in the control of L. donovani in GKO mice.

In addition to inducing IFN-γ, IL-12 is also known to enhance expression of TNF-α (23), a cytokine with separate effects not necessarily dependent on the presence of IFN-γ as a cofactor (28, 38). In addition, whereas IFN-γ normally induces TNF-α expression by the activated macrophage, some reports indicate IFN-γ-independent induction of TNF-α expression and have suggested that in the absence of TNF-α, IFN-γ is ineffective in control of infection (30, 31, 37, 39). This latter conclusion is supported by results from a prior study in IFN-γ-intact normal BALB/c mice (10) in which the antileishmanial effect of exogenous IL-12 was reversed equally well by either anti–IFN-γ or anti–TNF-α treatment. Whereas these latter results raise the possibility of a direct effect for TNF-α independent of IFN-γ in normal mice, they appear more consistent with the notion that both endogenous TNF-α and IFN-γ are required for optimal expression of IL-12–induced antileishmanial activity (10). However, our results here in GKO mice clearly suggest that TNF-α induced by exogenous IL-12 (or by L. donovani infection alone) can act by itself in the absence of IFN-γ. In addition, other cytokines with documented antileishmanial activity such as GM-CSF (12) may also play a role in the IL-12–stimulated control observed here; for instance, IL-12 also induces GM-CSF mRNA expression in livers of infected GKO mice (data not shown). However, the clear-cut effect of anti–TNF-α in IL-12–treated GKO mice indicates that TNF-α is both necessary and sufficient to mediate the effect of IL-12 in the absence of IFN-γ.

It should also be pointed out that treatment of GKO mice with IL-12 has been reported to induce no protective effect in models of infection caused by M. tuberculosis and T. gondii (40, 41). The use of different test pathogens and variations in doses of IL-12, or in administration routes and schedules may explain these contrary results. However, another possible explanation, at least in mycobacterial models, may relate to the apparently more strict requirement for endogenous IFN-γ in defense against these particular pathogens (42, 43).

TNF-α and IFN-γ act synergistically to induce synthesis of NO in normal mice (36), and depletion of either cytokine increases mortality after sublethal challenge with various microorganisms (31, 44). In GKO mice, NO synthesis in response to Bacillus Calmette-Guérin infection is depressed but not absent (3, 35). Similarly, in our model, while qualitative detection of iNOS mRNA in livers of infected GKO mouse was delayed and apparently incomplete, iNOS mRNA was detected in 50% of these animals at week 4. In addition, IL-12 treatment enhanced iNOS mRNA in GKO mice, also supporting the notion that this antimicrobial mechanism can be mobilized in the absence of endogenous IFN-γ, likely via endogenous TNF-α (Table 8). The capacity of the iNOS inhibitor, AG (16), to abolish the antileishmanial effect of IL-12 in GKO mice suggests in vivo relevance for these observations.

Two particular aspects of granuloma formation in GKO mice, which was delayed and persistently immature but not altogether absent, warrant comment. First, single parasitized Kupffer cells with no evidence of fusion or any surrounding cellular reaction were present at all timepoints even up to 12 wk after infection. These results (Table 1) provide firm evidence of the critical role of endogenous IFN-γ in macrophage fusion, cell recruitment, and granuloma assembly. Second, however, the capacity of exogenous IL-12 to accelerate and enhance the development of mature granulomas, an effect not apparent in a previous study in IFN-γ-intact mice (10), also demonstrated a separate IFN-γ-independent pathway active in the tissue granulomatous response. Because endogenous TNF-α is not essential for granuloma formation in this model (15), we suspect that factors other than TNF-α are involved in the tissue reaction stimulated by IL-12. The activity of GM-CSF, the expression of which is induced by IL-12 in L. donovani–infected GKO mice, might be a possible compensatory mechanism of granuloma assembly in the absence of endogenous IFN-γ. GM-CSF readily stimulates myelomonocytic cell influx into areas of developing granulomas in L. donovani–parasitized tissues of normal mice (12).

In summary, our results demonstrate the presence of spontaneously developing and IL-12–inducible intracellular antileishmanial effects in the absence of endogenous IFN-γ, indicating that this IFN-γ-independent mechanism is largely mediated by TNF-α, and suggest that the iNOS system appears to be a major antimicrobial effector mechanism in this IFN-γ-independent pathway.
References

1. Squires, K.E., R.D. Schreiber, M.J. McElrath, B.Y. Rubin, S.L. Anderson, and H.W. Murray. 1989. Experimental visceral leishmaniasis role of endogenous IFN-γ in host defense and tissue granulomatous response. J. Immunol. 143:4244–4249.

2. Murray, H.W. 1990. Effect of continuous administration of interferon-γ in experimental visceral leishmaniasis. J. Infect. Dis. 161:992–994.

3. Dalton, D.K., S. Pitts-Meek, S. Keshav, I.S. Figari, A. Bradley, and T.A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science (Wash. DC). 159:1739–1742.

4. Graham, M.B., D.K. Dalton, D. Giltinan, V.L. Braciale, T.A. Stewar, and T.J. Braciale. 1993. Response to influenza infection in mice with a targeted disruption in the interferon-γ gene. J. Exp. Med. 178:1725–1732.

5. Cooper, A.M., D.K. Dalton, T.A. Stewart, J.P. Griffin, D.G. Russell, and I.M. Orme. 1993. Disseminated tuberculous in interferon-γ-deficient mice. J. Exp. Med. 178:2243–2247.

6. Wang, Z., S. Zheng, D. Corry, D.K. Dalton, R.A. Seder, S.L. R einer, and R.M. Locksley. 1994. Interferon-γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc. Natl. Acad. Sci. USA. 91:12932–12936.

7. Wang, Z., S.L. R einer, S. Sheng, D.K. Dalton, and R.M. Locksley. 1994. CD4+ effector cells default to the Th2 pathway in interferon-γ-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367–1371.

8. Amir, P., M. Haak-Frendscho, K. Robbins, J.H. Mc Kerrow, T. Stewart, and P. Jardieu. 1994. Anti-immunoglobulin E treatment decreases worm burden and egg production in S. mansoni-infected normal and interferon-γ knockout mice. J. Exp. Med. 180:43–51.

9. Sambrook, J., E.F. Fritsch, and T. Maniatis. 1989. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

10. Murray, H.W., and J. Hariprashad. 1995. Interleukin-12 is required for the T-lymphocyte-independent induction of interferon-γ by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc. Natl. Acad. Sci. U.S.A. 90:6115–6119.

11. Seder, R.A., R. Gazzinelli, A. Sher, and W.E. Paul. 1993. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sci. USA. 90:10188–10192.

12. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridges innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251–261.

13. Morris, S.C., K.B. Madden, J.J. Adamovicz, W.C. Gause, B.R. Hubbard, M.K. Gately, and F.D. Finkelman. 1994. Effects of IFN-γ on in vivo cytokine gene expression and Ig isotype selection. J. Exp. Med. 175:1047–1056.

14. Brunda, M.J. 1994. Interleukin-12. J. Leuk. Biol. 55:280–288.

15. Naume, B., A.C. Johnsen, T. Espesvik, and A. Sondam. 1993. Gene expression and secretion of cytokines and cytokine receptors from highly purified CD56+ natural killer cells stimulated with interleukin-2, interleukin-7, and interleukin-12. Eur. J. Immunol. 23:1831–1838.

16. Liew, F.Y., S. Millott, C. Parkinson, R.M. Palmer, and S. Montag. 1990. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J. Immunol. 144:4794–4797.

17. Green, S.J., M.S. Meltzer, J.B. Hibbs, and C.A. Nacy. 1990. Activated macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 144:278–283.

18. Appelberg, R., A.G. Castro, J. Pedroza, R.A. Silva, I.M. Orme, and P. Minoprio. 1994. Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of M. tuberculosis avium infection. Inf. Immn. 62:3962–3971.

19. Dumarey, C.H., V. Labrousse, R. Astogi, B.B. Vargaftig, and M. Bachelet. 1994. Selective macrophages destroy intracellular Leishmania major amastigotes by an L-arginine-dependent killing mechanism. J. Immunol. 154:12986–12992.

20. Roach, T.I., A.F. Kiderlen, and J.M. Blackwell. 1991. Role of inorganic nitrogen oxides and tumor necrosis factor-alpha in killing Leishmania donovani amastigotes in gamma-interferon lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains. Inf. Immun. 59:3935–3944.

21. Feng, H., V.L. Popov, and D.H. Walker. 1994. Depletion of IL-12 Enhances IFN-γ-independent Antileishmanial Activity.
gamma interferon and tumor necrosis factor-alpha in mice with Rickettsia ononi-infected endothelium: impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease. Infect. Immun. 62:1952–1960.

32. Murray, H.W., C.W. Juangbhanich, C.F. Nathan, and Z.A. Cohn. 1979. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J. Exp. Med. 150:950–964.

33. Nathan, C.F., H.W. Murray, and Z.A. Cohn. 1980. The macrophage as an effector cell. N. Engl. J. Med. 303:622–626.

34. Murray, H.W. 1982. Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-independent killing of intracellular Leishmania donovani. J. Immunol. 129:351–357.

35. Chan, J., Y. Xing, R.S. Magliosso, and B.R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111–1122.

36. Nathan, C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6:3051–3064.

37. Nacy, C.A., A.I. Meierovics, M. Belosevic, and S.J. Green. 1991. Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology. 59:182–184.

38. Pawelec, G., K. Schaudt, A. Rohen, and F.W. Busch. 1989. Differential secretion of tumor necrosis factor-alpha and granulocyte/macrophage colony stimulating factors but not interferon-gamma from CD4+ compared to CD8+ human T cell clones. Eur. J. Immunol. 19:197–200.

39. Liew, F.Y., C. Parkinson, S. Millott, A. Severn, and M. Carrier. 1990. TNF-alpha mediates host protection against cutaneous leishmaniasis. Immunology. 69:570–573.

40. Flynn, J.L., M.M. Goldstein, K.J. Triebold, J. Sypek, S. Wolf, and B. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515–2524.

41. Scharton-Kersten, T.M., T.A. Wynn, E.Y. Denkers, S. Bala, E. Grunvald, S. Heiny, R.T. Gazzinelli, and A. Sher. 1996. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157:4045–4054.

42. Jouanguy, E., F. Altare, S. Lamhamedi, P. Revy, J. Emile, M. Newport, M. Levin, S. Blanche, A. Fischer, and J. Casanova. 1996. Interferon-gamma-receptor deficiency in an infant with fatal Bacille Calmette-Guerin infection. N. Engl. J. Med. 335:1956–1961.

43. Newport, M.J., C.M. Huxley, S. Huston, C.M. Hawrylowicz, B.A. Oostra, R. Williamson, and M. Levin. 1996. A mutation in the interferon-gamma receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941–1949.

44. Green, S.J., C.A. Nacy, R.D. Schrieber, D.L. Granger, R.M. Crawford, M.S. Metzler, and A.H. Fortier. 1993. Neutralization of gamma interferon and tumor necrosis factor-alpha blocks in vivo synthesis of nitrogen oxides from l-arginine and protection against Francisella tularensis infection in Mycobacterium bovis BCG-treated mice. Infect. Immun. 61:689–698.

45. Harty, J.T., and M.J. Bevan. 1995. Specific immunity to Listeria monocytogenes in the absence of IFN-gamma. Immunity. 3:109–117.